Background: Cigarette smoke have adverse effects in the control of asthma and chronic rhinosinusitis (CRS). Interleukin (IL)-17A, the signature cytokine of helper T 17 cells and group 3 innate lymphoid cells (ILC3), has been reported to link with resistance to therapy in airway inflammation. This study aimed to investigate the impact of cigarette smoking and IL-17A activation on the clinical outcomes of asthmatic patients with chronic rhinosinusitis.
Introduction
Chronic rhinosinusitis (CRS) is frequently associated with asthma (1) , and its presence is related to asthma severity. Among patients with asthma and CRS, pulmonary function and asthma control were closely related to the severity of nasal symptoms (2) . Exposure to cigarette smoke has been linked to a higher prevalence and severity of CRS (3) (4) (5) , contributing to increased nasal congestion, irritation, and airflow resistance. Several studies demonstrated that exposure to smoking diminishes long-term post-operative improvement of quality of life, delays olfactory recovery, and increases the risk of revision surgery after endoscopic sinus surgery (ESS) (6, 7) . Although the type 2 inflammatory cytokines are considered as major drivers of airway inflammation in patients with CRS and asthma (8, 9) , interleukin (IL)-17A has been linked to neutrophil recruitment, mucosa remodeling, and resistance to corticosteroidbased therapy in airway diseases (10) (11) (12) . Helper T (Th) 17 cells are effector T-cell subsets and secrete pro-inflammatory cytokines such as IL-17A, IL-17F, and IL-22, which is implicated in the pathogenesis of several inflammatory diseases (13) . Group 3 innate lymphoid cells (ILC3s) have recently emerged as one of the producers of IL-17A (14) , are prevalent at mucosal sites, and protect mucosal surfaces (15) . In an animal study, ILC3 cell-producing IL-17A facilitated the development of airway hyperreactivity (16) .
Smokers with asthma develop neutrophilic airway inflammation, which is related to cigarette smoke-induced production of IL-17A together with other environmental stimuli acting on airway epithelial cells that induce neutrophil chemotaxis (17) . Our recent study demonstrated that current smoking was associated with the augmented expression of IL-17A in the nasal tissues and with an increase in the number of unexpected emergency clinic visits in patients with asthma (18) . Thus, IL-17A plays a crucial role in cigarette smoke-induced airway inflammation and its resistance to the current therapeutic regimens.
Aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor that modulates immune reactions, responds to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; dioxin) and other related polycyclic aromatic hydrocarbons (PAHs) (19) . After binding to ligand, AhR translocates to the nucleus and forms a heterodimer with the AhR nuclear translocator (ARNT). This AhR-ARNT complex binds to a dioxin-responsive element and initiates the transcription of genes that comprise the AhR gene battery, including cytochrome P450 family and cyclooxygenase-2 enzymes (COX-2) (20, 21) . PAH is an important constituent of cigarette smoke that triggers AhR activation (22, 23) . Activation of AhR may be essential for the differentiation of ILC3 and Th17 cells, as well as the consequent IL-17A-mediated immune response (24, 25) . Therefore, we hypothesise that AhR-, ILC3-, and IL-17A-mediated immune responses may play a crucial role in cigarette smokerelated airway inflammation and its resistance to the current therapeutic regimens. Thus, this study aimed to investigate the impact of cigarette smoking on the clinical outcomes of asthmatic patients with CRS and its association with IL-17A activation.
Materials and methods

Patients
We prospectively recruited patients with CRS and asthma who were managed in the Departments of Thoracic Medicine and Otolaryngology between August 2013 and June 2016. Patients with asthma who fulfilled the diagnostic criteria of the Global Initiative for Asthma (GINA) guidelines (26) and had as a co-morbidity, CRS (defined by the criteria from the European position paper (27) and based on the symptoms and findings of nasal endoscopy and sinus computed tomography (CT)), were enrolled in the study. Patients with asthma [1] with regular follow-up for at least 1 year; [2] who have failed a 3-month maximal medical treatment, including intranasal topical corticosteroids, antihistamines, and broad-spectrum oral antibiotics; and [3] who planned to receive an ESS for CRS were included in the study.
Patients with asthma were treated based on the GINA guidelines to achieve well-controlled status for more than 6 months before the surgery, that allowed them to undergo nasal surgery under general anaesthesia. Patients with previous nasal surgeries or major medical disorders, such as diabetes, nephrotic diseases, autoimmune disorders, immunodeficiencies, malignancies, and other chronic illnesses, were excluded. Another seven asthmatic patients without CRS (confirmed by sinus CT) and smoking were enrolled as a control group during the performance of septomeatoplasty and/or turbinoplasty for nasal obstruction.
The study was approved by the institutional review board of the Chang Gung Memorial Hospital (IRB number: 101-5069B and 103-7085B). All participants signed an informed consent before enrolment.
The patients' clinical characteristics were recorded. They were .
Statistical analyses
The data were presented as mean ± standard error and statistically analysed using the GraphPad Prism 5 (GraphPad Prism 
Results
Clinical characteristics of the study population
The general characteristics of patients with asthma and CRS, including 15 smokers and 18 non-smokers, and 7 non-smokers with asthma without CRS are summarised in Table S2 . There was no difference in age, severity of sinusitis, presence of nasal polyps, lung function, and medications between smokers and non-smokers with asthma and CRS, except for gender. Nasal polyps were found by nasal endoscopic examination in two of 15 smokers with asthma and CRS (13.3%) and in six of 18 nonsmokers with asthma and CRS (33.3%).
Clinical outcomes after nasal surgery
Nasal surgery improved sinonasal symptoms ( Figure 1A ), asthma control ( Figure 1B ), asthma treatment ( Figure 1C ), and pulmonary function ( Figure 1D ). Compared to non-smokers, smokers had poorer improvement in asthma control ( Figure 1E ), pulmonary function ( Figure 1F ), and asthma treatment ( Figure 1G ), but not in nasal symptoms ( Figure 1H ) after nasal surgery for CRS.
asked if they regularly used cigarettes or smoked other forms of tobacco pre-operatively. Patients were considered as smokers if they reported regular or on-going smoking in the last 12 months (7) and non-smokers if they never used cigarette regularly.
All patients received a thorough nasal endoscopy examination and sinus CT, which were scored using the Lund-Kennedy endoscopy score and Lund-Mackay CT score preoperatively.
Pulmonary function tests, including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV 1 ), and FEV 1 /FVC ratio,
were measured before and 6 months after nasal surgery. The
Sino-Nasal Outcome Test-22 (SNOT-22) and Asthma Control
Test (ACT) questionnaires were applied in order to evaluate the severity of sinonasal symptoms and the level of asthma control at the same time.
Collection and processing of specimens
Nasal mucosal specimens were rinsed in phosphate-buffered saline (pH 7.6), stored at liquid nitrogen at -70°C, and then processed for immunostaining and real-time polymerase chain reaction (PCR).
RNA extraction/reverse transcription and real-time PCR
Frozen nasal tissue was homogenised (Retsch, Haan, Germany).
Total RNA was extracted from nasal specimens using the RNeasy Mini Kit (Qiagen GmbH, Strasse, Germany) and quantified by NanoDrop (Thermo Scientific, Barrington, Ill). Reverse transcription was performed with random hexamer primers using the HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Real-time PCR was done using the TaqMan assay with primers specific for the target genes (Table S1) values were normalised to GAPDH, and the relative mRNA levels of the target genes were analysed using the ΔΔCt method.
Immunohistochemistry for IL-17A expression
Paraffin sections were de-waxed in xylene and rinsed in absolute alcohol, and incubated in 3% H 2 O 2 for 30 min to quench the endogenous peroxidase. The sections were microwaved and incubated in 0.2% normal swine serum (DAKO, CA, USA).
The sections were incubated with the specific IL-17A antibody (diluted 1:100) or non-specific purified rabbit IgG (diluted , n=7, p=0.006) ( Figure 3B ). AhR nuclear localisation was not limited to the airway epithelium, but was also seen in the subepithelial cells including the inflammatory cells ( Figure   3A ). The number of AhR-ARNT positive cells was highly correlated to the level of IL-17 mRNA expression in the nasal tissues Anti-asthma medication (n) 0.56
Step 1 (as-needed SABA) 0 0 0
Step 2 (low dose ICS) 4 4 1
Step 3 (low dose ICS + LABA) 6 7 2
Step 4 (medium/high dose ICS + LABA ) 3 0 1
Step 5 (anti-IgE) 2 7 3
Data are represented as mean ± SE. CRS, chronic rhinosinusitis; CT, computed tomography; IgE, immunoglobulin E; WBC, white blood cell; SNOT-22, sino-nasal outcome test-22; ACT, asthma control test; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; L, liter; SABA, short-acting beta2-agonist; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist. *Categorical variables were compared using Fisher's exact test and continuous variables were analyzed using the Mann-Whitney U test or Kruskal-Wallis H test when comparing between two or three groups. †Analyses between smoker and non-smoker with CRS and asthma. The mRNA levels of IL-4 (G) and IL-12A (H) in nasal tissues were not different between these three groups. The significance is indicated. Cigarette smoke contains many AhR-activating ligands, which may contribute to AhR-dependent immune response in mucosal cells exposed to chronic cigarette smoke (23) In this study, the expression of AhR, nuclear AhR-ARNT, CYP1A1, (NCR + ) ILC3, IL-17A, IL-22, and COX-2 were elevated in the nasal mucosa of smokers with CRS and asthma. After binding to ligands, the AhR translocates to the nucleus and forms a heterodimer with the ARNT in the nasal tissue and has been shown to enhance the Th17 and ILC3 development (24) and induce the expression of the cytokine IL-22 and IL-17A in these cells (28) . AhR may regulate transcription factors, cellular proteins, and responses to chemical compounds via the AhR-ARNT, NF-κB, and p38-MAPK signalling pathways (29) .
A previous study showed that the elevated IL-17A expression in the lung explants from both non-COPD and COPD patients was dependent on the NF-κB pathways activated via exposure to cigarette smoke (30) . Smoke and other environmental stimuli act on airway epithelial cells to induce neutrophil chemotaxis along with neutrophilic inflammation of airways by producing IL-17A in asthmatic smokers (17) . Thus, the elevated IL-17A mRNA expression in the nasal tissues was correlated with those of AhR, AhRR, CYP1A1, and cell numbers with positive nuclear AhR-ARNT immunostaining. In addition, ILC3 cells, which express the transcription factors RORγt and AhR, have a high capacity to produce IL-17A and IL-22 (31) . AhR knock-out mice have reduced numbers of IL-22-producing ILC3 subset in the gut (31, 32) . AhR activation plays an important role in the maintenance and function of IL-22-producing ILC3s in the gut (31) . (NCR + ) ILC3 cells secrete IL-22 that highlights its critical role in activating the effector functions of committed Th17 cells, contributing to the development of inflammatory disease (33) . Therefore, the cell numbers of (NCR (34) . Additionally, previous studies demonstrated that inflammatory responses of nasal epithelial cells could reflect those of bronchial cells, and therefore, nasal epithelial cells could be used as surrogates for lower airway cells (35) . Hence, we considered the same situation of high IL-17A secretion in the lower airways of smokers.
IL-17A increases the neutrophil-associated cytokines, CXCL8, IL-1β, IL-6, and GM-CSF from the airway epithelial cells, endothelial cells, and fibroblasts to mediate neutrophilic inflammation (31, 36) .
An IL-17A-related neutrophilic airway inflammation serves as a phenotype of severe asthma, mainly a steroid-insensitive Th2low phenotype (36) . Thus, IL-17A may be a key driver of disease exacerbation, resistance to corticosteroids, enhanced airway hyperresponsiveness, and increased airway remodeling in severe asthma (9, 10, 16, 34) . Therefore, the increased expression of IL-17A in the nasal tissues of smokers who suffer from CRS and asthma appears to impair asthma control. In this and other studies, asthma control, including symptom scores, pulmonary function, steroid dependence, and emergency department visits, improve after an ESS treatment for CRS in patients with asthma (20, 37) .
However, this study further disclosed that the improvement in asthma control was less in patients who smoke cigarettes than those who do not smoke. Cigarette smoking seems to offset the benefit of nasal surgery, which is the reduction of inflammatory load in the airways.
Previous studies indicated that the induction of IL-17A via exposure to diesel exhaust particles, traffic-related air pollution, and PAH led to severe asthma (38) .
Van Voorhis et al. demonstrated that the Th17 polarisation was enhanced in an AhR-dependent manner through the stimulation of atmospheric particulate matter (PM) in the lungs of mice . PAHs present in the PM were the likely sources of Th17-promoting activity (39) . Cigarette smoke contains substantial PAHs (22) . Taken together, IL-17A-mediated inflammation via AhR activation induced by cigarette smoke contributed to corticosteroid resistance and airway flow obstruction in patients with asthma.
IL-17A is primarily produced by Th17 cells (14, 15) . Many immune cells, such as ILC3 (16) , B cells (40) , and gdT cells (41) are also important cellular sources of IL-17A. In humans, the expression of NCR2, namely, NK cell activating receptor 44, defines two subpopulations among ILC3s (14) . (NCR + ) ILC3s are scattered throughout the lamina propria of intestinal and airway mucosa (15) . However, (NCR-) ILC3 comprises lymphoid-tissue-inducer (LTi) cells and
LTi-like cells that usually aggregate with stromal, dendritic, and B cells in the cryptopatches, isolated lymphoid follicles, or mature isolated lymphoid follicles (14, 15) . ILCs in the intestinal tract and lower airways are well-studied (42) . However, few data about the relative abundance and characteristics of ILC3 cells in the human nasal mucosa are available (43) . This study showed that cigarette smoke may increase the number of (NCR + ) ILC3 cells via AhR activation, which contributes to the production of IL-17A in the nasal mucosa of smokers with asthma and CRS.
Our study revealed that COX-2 was upregulated in the nasal tissues of smokers with asthma and CRS through AhR activation.
The promoter activity of the COX-2 gene was induced by AhR ligands (44) , and this activation increased the binding of the AhR to XRE in the COX-2 promoter. Data revealed that COX-2 mRNA in smokers and non-smokers with asthma and CRS (n=33) was correlated with the mRNA expression of AhR, AhRR, and CYP1A1
in the nasal tissues (data not shown). The recruitment of AhR to target promoter genes such as CYP1A1 has been associated with the recruitment of transcription coactivators, such as NF-κB, NF-IL-6, and C/EBPb (45) , thus contributing to the production of COX-2. Smoking induces an array of inflammatory mediators and cytokines, such as COX-2, MMP-1, and MMP-9, and lead to chronic inflammation and airway remodeling in patients with asthma and rhinosinusitis. The poorer improvement of asthma control in smokers with asthma and CRS after nasal surgery may be partly related to this pathway.
In this study, poorer improvements in asthma control, pulmonary function, and asthma treatment, but not in nasal symptoms 6 months after nasal surgery for CRS, were observed in smokers than in non-smokers. Previous studies revealed that exposure to smoking diminishes long-term outcomes and increases the risk of revision surgery after ESS (3, 7) . However, short-term outcomes of CRS after ESS in smokers was diverse as reported in the literature (46) . Rudmik et al. demonstrated a significant difference in the prevalence of worsening postoperative outcomes among heavy smokers, light smokers, and non-smokers, indicating that smoking volume may contribute to diverse results (6) .
Smokers with asthma and CRS comprise a small population of patients with asthma, but have the highest health care costs among asthma phenotypes (9, 26, 47) . Therefore, defining the role of IL-17A and its associated immune pathway is imperative in designing, implementing, and tailoring therapeutics to successfully treat these patients. Future novel therapeutics that target IL-17A or AhR-related inflammatory responses or modulate the function of ILC3s may be beneficial for those with asthma or CRS that is refractory to current standard treatments.
This study has several limitations that warrant consideration.
First, we recruited patients with asthma with and without CRS.
It would have been better to include patients without airway diseases and CRS in the normal control group. However, it is difficult to recruit appropriate and healthy control patients because of the ethical considerations involved in performing an invasive biopsy on the nasal mucosa. Our ethics committee did not allow us to include this control group. Thus, non-smokers with asthma without CRS were chosen as control population.
Second, the sample size was small. A large-scale study is necessary for the subgroup analysis of different phenotypes of CRS.
Third, long-term studies are needed to investigate the continuing impact of cigarette smoking on the clinical outcomes of patients with CRS and asthma. Fourthly, we have not used flow cytometry which is an important method for the study of innate lymphoid cells (ILCs) isolated from tissue specimens that would have allowed for a multiparameter analysis of ILC3 and ILC2
populations. In the future, we will conduct the flow cytometry study to elucidate in the tissue cell suspensions of nasal mucosa these ILC3 and ILC2 populations.
Conclusion
Cigarette 
